AstraZeneca has taken the decision not to move a PCSK9-targeting antisense drug licensed from Ionis into a phase 3 programme, removing a competitor to Novartis' rival therapy Leqvio.
With a reorganisation of Novartis now nearing completion, the Swiss pharma group is laying out its plans for growth at a meeting with investors and analysts, which it says will be driven ma
Although a tone of respectful sobriety lay over the PM Society Awards this year, as the nation’s citizens came from far and wide to London to pay their final respects to Her Majesty Queen Elizabeth
It's well known that where you live can have a profound impact on your risk of heart attack or stroke, but the exact reasons behind that inequality can be hard to tease out.